A prospective, multicenter, randomized, three-arm, parallel-controlled clinical study of the efficacy and safety of an electrocooled ablation system for the treatment of lung tumors

INTERVENTION: Test group:Standard treatment plus electrocooling ablation system;Standard treatment group:Standard treatment of lung tumors (clinical guidelines for the treatment of primary lung cancer and metastatic lung cancer);Control group:Standard treatment plus cryosurgery system; CONDITION: Lung tumors (primary lung cancer and metastatic lung cancer) PRIMARY OUTCOME: Efficiency at 3 months after tumor ablation; SECONDARY OUTCOME: Efficiency at 1,3, 6 and 12 months after ablation;Immediate efficacy after ablation;Changes in CT values after ablation;Disease control rates at 1, 3, 6, and 12 months after ablation;Local recurrence rates at 1, 3, 6, and 12 months after ablation;Serum tumor marker test: CEA, CYFRA21‐1, SCC;ECOG Rating;Overall survival rate at 1 year after surgery; INCLUSION CRITERIA: 1) Age 18 to 85 years old (including 18 and 85 years old), both sexes; 2) Patients with clearly diagnosed primary lung cancer or metastatic lung cancer, with the number of unilateral lung lesions = 3, target lesions measurable, 1 cm < target lesion < 6 cm, requiring ablative surgical treatment; 3) Those who cannot tolerate surgical resection or refuse it; 4) ECOG physical status score 0 2; 5) Voluntary participation with the free will of the subject or legal representative, and signed informed consent form.